Orthocell (ASX:OCC) FCF Margin % : -57.49% (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Orthocell FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Orthocell's Free Cash Flow for the six months ended in Jun. 2024 was A$-2.25 Mil. Orthocell's Revenue for the six months ended in Jun. 2024 was A$3.91 Mil. Therefore, Orthocell's FCF Margin % for the quarter that ended in Jun. 2024 was -57.49%.

As of today, Orthocell's current FCF Yield % is -7.90%.

The historical rank and industry rank for Orthocell's FCF Margin % or its related term are showing as below:

ASX:OCC' s FCF Margin % Range Over the Past 10 Years
Min: -810.66 Med: -458.64 Max: 329.04
Current: -140.11

During the past 11 years, the highest FCF Margin % of Orthocell was 329.04%. The lowest was -810.66%. And the median was -458.64%.

ASX:OCC's FCF Margin % is ranked better than
50.33% of 1049 companies
in the Biotechnology industry
Industry Median: -143.87 vs ASX:OCC: -140.11

Orthocell FCF Margin % Historical Data

The historical data trend for Orthocell's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orthocell FCF Margin % Chart

Orthocell Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

FCF Margin %

Get a 7-Day Free Trial

-737.78

-473.67

-443.60

329.04

-140.11

Orthocell Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
FCF Margin %	Get a 7-Day Free Trial															-331.12	1,874.73	-56.48	-370.04	-57.49

Competitive Comparison of Orthocell's FCF Margin %

For the Biotechnology subindustry, Orthocell's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orthocell's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orthocell's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Orthocell's FCF Margin % falls into.

Orthocell FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Orthocell's FCF Margin for the fiscal year that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2024 )	/	Revenue (A: Jun. 2024 )
	=	-7.447	/	5.315
	=	-140.11 %

Orthocell's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-2.248	/	3.91
	=	-57.49 %

Orthocell FCF Margin % Related Terms

Thank you for viewing the detailed overview of Orthocell's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Orthocell Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orthocell Ltd (ASX:OCC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

90 South Street, Building 191, Murdoch University, Murdoch, Perth, WA, AUS, 6150

Website

https://www.orthocell.com.au

Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialisation of cell therapies and related technologies. Its product includes CelGro is a naturally derived collagen medical device for tissue repair and Ortho-ATI is a first-in-class cell therapy for the treatment of chronic tendon injuries.